Roche and Ionis report 43.1% proteinuria reduction with sefaxersen in Phase 3 IgA nephropathy trial
Roche and Ionis report a 43.1% Phase 3 proteinuria reduction with sefaxersen. Two-year kidney function results remain the next major test.
Pharma & Biotech